SG3 Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

SG3 Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30,000	Closed	-$946K	–	181
2022 Q4	$946K	Buy	30,000 +15,000	+100%	+$423K	0.14%	87
2022 Q3	$424K	Buy	+15,000	New	+$447K	0.06%	152
2022 Q2	–	Sell	-20,500	Closed	-$718K	–	925
2022 Q1	$718K	Buy	+20,500	New	+$599K	0.02%	529
2021 Q4	–	Sell	-10,000	Closed	-$295K	–	1343
2021 Q3	$295K	Buy	+10,000	New	+$281K	0.01%	709

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SG3 Management's CERE Position: Q3 2022 in Review

SG3 Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 10,000 shares — an estimated $298K sold.

SG3 Management first reported a position in CERE in Q2 2022 and held it in 1 quarter. The position peaked at $264K in Q2 2022. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

SG3 Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 10,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $298K.
SG3 Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
SG3 Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $264K in Q2 2022.
114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.